MPN相关突变基因及JAK2抑制剂治疗
MPN-Related Mutations and JAK2 Inhibitor Therapy
DOI: 10.12677/ACM.2023.131037, PDF,   
作者: 杨 骏：华北理工大学研究生院，河北 唐山
关键词: MPN；JAK2；CALR；MPL驱动突变；JAK2抑制剂；MPN； JAK2； CALR； MPL Drive Mutation； JAK2 Inhibitors
摘要: 骨髓增殖性肿瘤(MPN)是一组由髓系细胞过度产生而引起的疾病，大多数MPN都有一个可识别的驱动突变，如JAK2V617F突变、MPL突变、CALR突变，此外还包括一些其他非驱动突变，如ASXL1、DNMT3A和TET2等。由JAK2V617F、MPL和CALR突变激活的JAK2信号通路已成为MPN患者靶向治疗开发的一个重点，JAK2抑制剂已成为治疗MPN不可或缺的一部分，本综述将讨论MPN相关突变基因的发病机制、JAK2抑制剂的相关治疗。
Abstract: Myeloid proliferative tumors (MPNS) are a group of diseases caused by overproduction of myeloid cells. Most MPNS have an identifiable driver mutation, such as JAK2V617F mutation, MPL mutation, CALR mutation, and some other non-driver mutations, such as ASXL1, DNMT3A, and TET2. JAK2 signaling pathways activated by JAK2V617F, MPL and CALR mutations have become a focus in the development of targeted therapies for patients with MPN. JAK2 inhibitors have become an integral part of the treatment of MPN. This review will discuss the pathogenesis of MPN-related mutations and the treatment of JAK2 inhibitors.
文章引用：杨骏. MPN相关突变基因及JAK2抑制剂治疗[J]. 临床医学进展, 2023, 13(1): 238-245. https://doi.org/10.12677/ACM.2023.131037

参考文献

[1] Arber, D.A., Orazi, A., Hasserjian, R., et al. (2016) The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood, 127, 2391-2405. [Google Scholar] [CrossRef] [PubMed]
[2] Stuckey, R. and Gómez-Casares, M.T. (2021) Recent Ad-vances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. International Journal of Molecular Sciences, 22, 5042. [Google Scholar] [CrossRef] [PubMed]
[3] Jia, R. and Kralovics, R. (2020) Progress in Elucidation of Molecular Pathophysiology of Myeloproliferative Neoplasms and Its Application to Therapeutic Decisions. International Journal of Hematology, 111, 182-191. [Google Scholar] [CrossRef] [PubMed]
[4] Takenaka, K. (2020) Progress in Elucidation of Molecular Path-ophysiology and Its Application in Therapeutic Decision-Making for Myeloproliferative Neoplasms. International Jour-nal of Hematology, 111, 180-181. [Google Scholar] [CrossRef] [PubMed]
[5] Szybinski, J. and Meyer, S.C. (2021) Genetics of Myeloprolif-erative Neoplasms. Hematology/Oncology Clinics of North America, 35, 217-236. [Google Scholar] [CrossRef] [PubMed]
[6] Passamonti, F., Elena, C., Schnittger, S., et al. (2011) Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations. Blood, 117, 2813-2816. [Google Scholar] [CrossRef] [PubMed]
[7] Scott, L.M., Tong, W., Levine, R.L., et al. (2007) JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. The New England Journal of Medicine, 356, 459-468. [Google Scholar] [CrossRef] 
[8] McNally, R., Toms, A.V. and Eck, M.J. (2016) Crystal Structure of the FERM-SH2 Module of Human Jak2. PLOS ONE, 11, e0156218. [Google Scholar] [CrossRef] [PubMed]
[9] Raivola, J., Haikarainen, T., Abraham, B.G. and Silvennoinen, O. (2021) Janus Kinases in Leukemia. Cancers, 13, 800. [Google Scholar] [CrossRef] [PubMed]
[10] Bharadwaj, U., Kasembeli, M.M., Robinson, P. and Tweardy, D.J. (2020) Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Infammation, Fbrosis, and Cancer: Rationale, Progress, and Caution. Pharmacological Reviews, 72, 486-526. [Google Scholar] [CrossRef] [PubMed]
[11] Dusa, A., Mouton, C., Pecquet, C., et al. (2010) JAK2 V617F Consti-tutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors. PLOS ONE, 5, e11157. [Google Scholar] [CrossRef] [PubMed]
[12] Wingelhofer, B., Neubauer, H.A., Valent, P., et al. (2018) Im-plications of STAT3 and STAT5 Signaling on Gene Regulation and Chromatin Remodeling in Hematopoietic Cancer. Leukemia, 32, 1713-1726. [Google Scholar] [CrossRef] [PubMed]
[13] Vainchenker, W. and Kralovics, R. (2017) Genetic Basis and Mo-lecular Pathophysiology of Classical Myeloproliferative Neoplasms. Blood, 129, 667-679. [Google Scholar] [CrossRef] [PubMed]
[14] (2020) Online Mendelian Iinheritance in Man: An Online Cat-alog of Human Genes and Genetic Disorders. Johns Hopkins University, Baltimore.
[15] Ding, J., Komatsu, H., Wakita, A., et al. (2004) Familial Essential Thrombocythemia Associated with a Dominant- Positive Activating Mutation of the c-MPL Gene, Which Encodes for the Receptor for Thrombopoietin. Blood, 103, 4198-4200. [Google Scholar] [CrossRef] [PubMed]
[16] Staerk, J., Lacout, C., Sato, T., et al. (2006) An Amphipathic Motif at the Transmembrane-Cytoplasmic Junction Prevents Autonomous Activation of the Thrombopoietin Receptor. Blood, 107, 1864-1871. [Google Scholar] [CrossRef] [PubMed]
[17] Mead, A.J. and Mullally, A. (2017) Myeloproliferative Neoplasm Stem Cells. Blood, 129, 1607-1616. [Google Scholar] [CrossRef] [PubMed]
[18] Tiedt, R., Coers, J., Ziegler, S., Wiestner, A., Hao-Shen, H., Bornmann, C., Schenkel, J., Karakhanova, S., De Sauvage, F.J., Jackson, C.W., et al. (2009) Pronounced Thrombocyto-sis in Transgenic Mice Expressing Reduced Levels of Mpl in Platelets and Terminally Differentiated Megakaryocytes. Blood, 113, 1768-1777. [Google Scholar] [CrossRef] [PubMed]
[19] Lannutti, B.J., Epp, A., Roy, J., Chen, J. and Josephson, N.C. (2009) Incomplete Restoration of Mpl Expression in the mpl/Mouse Produces Partial Correction of the Stem Cell-Repopulating Defect and Paradoxical Thrombocytosis. Blood, 113, 1778-1785. [Google Scholar] [CrossRef] [PubMed]
[20] Prins, D., Arias, C.G., Klampflfl, T., Grinfeld, J. and Green, A.R. (2020) Mutant Calreticulin in the Myeloproliferative Neoplasms. HemaSphere, 4, e333. [Google Scholar] [CrossRef] 
[21] Klampfl, T., Gisslinger, H., Harutyunyan, A.S., et al. (2013) Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. The New England Journal of Medicine, 369, 2379-2390. [Google Scholar] [CrossRef] 
[22] Rumi, E. and Cazzola, M. (2017) Diagnosis, Risk Strat-ification, and Response Evaluation in Classical Myeloproliferative Neoplasms. Blood, 129, 680-692. [Google Scholar] [CrossRef] [PubMed]
[23] Rumi, E., Pietra, D., Ferretti, V., et al. (2014) JAK2 or CALR Mutation Status Defines Subtypes of Essential Thrombocythemia with Substantially Different Clinical Course and Out-comes. Blood, 123, 1544-1551. [Google Scholar] [CrossRef] [PubMed]
[24] Rumi, E., Pietra, D., Pascutto, C., et al. (2014) Clinical Effect of Driver Mutations of JAK2, CALR, or MPL in Primary Myelofibrosis. Blood, 124, 1062-1069. [Google Scholar] [CrossRef] [PubMed]
[25] Tefferi, A., Lasho, T.L., Finke, C.M., et al. (2014) CALR vs JAK2 vs MPL-Mutated or Triple-Negative Myelofibrosis: Clinical, Cytogenetic and Molecular Comparisons. Leukemia, 28, 1472-1477. [Google Scholar] [CrossRef] [PubMed]
[26] Nangalia, J., Massie, C.E., Baxter, E.J., et al. (2013) So-matic CALR Mutations in Myeloproliferative Neoplasm with Nonmutated JAK2. The New England Journal of Medicine, 369, 2391-2405. [Google Scholar] [CrossRef] 
[27] How, J., Hobbs, G.S. and Mullally, A. (2019) Mutant Calreticulin in Myeloproliferative Neoplasms. Blood, 134, 2242- 2248. [Google Scholar] [CrossRef] [PubMed]
[28] Pietra, D., Rumi, E., Ferretti, V.V., Di Buduo, C.A., Milanesi, C., Cavalloni, C., Sant’Antonio, E., Abbonante, V., Moccia, F., Casetti, I.C., et al. (2016) Faculty Opinions Recommenda-tion of Differential Clinical Effects of Different Mutation Subtypes in CALR-Mutant Myeloproliferative Neoplasms. Leukemia, 30, 431-438. [Google Scholar] [CrossRef] [PubMed]
[29] Masubuchi, N., Araki, M., Yang, Y., Hayashi, E., Imai, M., Edahiro, Y., Hironaka, Y., Mizukami, Y., Kihara, Y., Takei, H., et al. (2020) Mutant Calreticulin Interacts with MPL in the Secretion Pathway for Activation on the Cell Surface. Leukemia, 34, 499-509. [Google Scholar] [CrossRef] [PubMed]
[30] Cabagnols, X., Favale, F., Pasquier, F., et al. (2016) Presence of Atypical Thrombopoietin Receptor (MPL) Mutations in Triple-Negative Essential Thrombocythemia Patients. Blood, 127, 333-342. [Google Scholar] [CrossRef] [PubMed]
[31] Milosevic Feenstra, J.D., Nivarthi, H., Gisslinger, H., et al. (2016) Whole-Exome Sequencing Identifies Novel MPL and JAK2 Mutations in Triple-Negative Myeloproliferative Neoplasms. Blood, 127, 325-332. [Google Scholar] [CrossRef] [PubMed]
[32] Michail, O., McCallion, P., McGimpsey, J., et al. (2020) Mu-tational Profling in Suspected Triple-Negative Essential Thrombocythaemia Using Targeted Next-Generation Sequencing in a Real-World Cohort. Journal of Clinical Pathology, 74, 808-811. [Google Scholar] [CrossRef] [PubMed]
[33] Tefferi, A., Lasho, T.L., Finke, C., Belachew, A.A., Wassie, E.A., Ketterling, R.P., Hanson, C.A. and Pardani, A. (2014) Type 1 vs. Type 2 Calreticulin Mutations in Primary Myelo-fibrosis: Differences in Phenotype and Prognostic Impact. Leukemia, 28, 1568-1570. [Google Scholar] [CrossRef] [PubMed]
[34] Lee, J., Godfrey, A.L. and Nangalia, J. (2020) Genomic Heterogeneity in Myeloproliferative Neoplasms and Applications to Clinical Practice. Blood Reviews, 42, Article ID: 100708. [Google Scholar] [CrossRef] [PubMed]
[35] Marneth, A.E. and Mullally, A. (2020) The Molecular Genetics of Myeloproliferative Neoplasms. Cold Spring Harbor Perspectives in Medicine, 10, a034876. [Google Scholar] [CrossRef] [PubMed]
[36] Morsia, E., Torre, E., Poloni, A., Olivieri, A. and Rupoli, S. (2022) Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications. International Journal of Molecular Sciences, 23, 4573. [Google Scholar] [CrossRef] [PubMed]
[37] Chachoua, I., Pecquet, C., El-Khoury, M., Nivarthi, H., Albu, R.I., Marty, C., Gryshkova, V., Defour, J.P., Vertenoeil, G., Ngo, A., et al. (2016) Thrombopoietin Receptor Activation by Myeloproliferative Neoplasm Associated Calreticulin Mutants. Blood, 127, 1325-1335. [Google Scholar] [CrossRef] [PubMed]
[38] Brkic, S. and Meyer, S.C. (2021) Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. Hemasphere, 5, e516. [Google Scholar] [CrossRef] 
[39] Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Nieder-wieser, D., Or, R., Szer, J., Wagner, E.M., Zuckerman, T., Mahuzier, B., et al. (2020) Ruxolitinib for Glucocorti-coid-Refractory Acute Graft-versus-Host Disease. The New England Journal of Medicine, 382, 1800-1810. [Google Scholar] [CrossRef] 
[40] Zeiser, R., Polverelli, N., Ram, R., Hashmi, S.K., Chakraverty, R., Middeke, J.M., Musso, M., Giebel, S., Uzay, A., Langmuir, P., et al. (2021) Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. The New England Journal of Medicine, 385, 228-238. [Google Scholar] [CrossRef] 
[41] Harrison, C., Kiladjian, J., Al-Ali, H., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., et al. (2012) JAK Inhibition with Ruxolitinib ver-sus Best Available Therapy for Myelofibrosis. The New England Journal of Medicine, 366, 787-798. [Google Scholar] [CrossRef] 
[42] Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., Di-Persio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., et al. (2012) A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. The New England Journal of Medicine, 366, 799-807. [Google Scholar] [CrossRef] 
[43] Vannucchi, A.M., Kiladjian, J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., Pane, F., Zachee, P., Mesa, R., et al. (2015) Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. The New England Journal of Medicine, 372, 426-435. [Google Scholar] [CrossRef] 
[44] Verstovsek, S., Vannucchi, A.M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., Pane, F., Zachee, P., Kirito, K., et al. (2016) Ruxolitinib versus Best Availa-ble Therapy in Patients with Polycythemia Vera: 80-Week Follow-Up from the RESPONSE Trial. Haematologica, 101, 821-829. [Google Scholar] [CrossRef] [PubMed]
[45] Passamonti, F., Griesshammer, M., Palandri, F., Egyed, M., Benevolo, G., Devos, T., Callum, J., Vannucchi, A.M., Sivgin, S., Bensasson, C., et al. (2017) Ruxolitinib for the Treatment of Inadequately Controlled Polycythaemia Vera without Splenomegaly (RESPONSE-2): A Randomised, Open-Label, Phase 3b Study. The Lancet Oncology, 18, 88-99. [Google Scholar] [CrossRef] 
[46] Griesshammer, M., Saydam, G., Palandri, F., Benevolo, G., Egyed, M., Callum, J., Devos, T., Sivgin, S., Guglielmelli, P., Bensasson, C., et al. (2018) Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 80-Week Follow-Up from the RESPONSE-2 Trial. Annals of Hematology, 97, 1591-1600. [Google Scholar] [CrossRef] [PubMed]
[47] Deininger, M., Radich, J., Burn, T.C., Huber, R., Paranagama, D. and Verstovsek, S. (2015) The Effect of Long-Term Ruxolitinib Treatment on JAK2p.V617F Allele Burden in Patients with Myelofibrosis. Blood, 126, 1551-1554. [Google Scholar] [CrossRef] [PubMed]
[48] Talpaz, M. and Kiladjian, J.-J. (2021) Fedratinib, a Newly Ap-proved Treatment for Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis. Leukemia, 35, 1-17. [Google Scholar] [CrossRef] [PubMed]
[49] Mullally, A., Hood, J., Harrison, C. and Mesa, R. (2020) Fedrat-inib in Myelofibrosis. Blood Advances, 4, 1792-1800. [Google Scholar] [CrossRef] [PubMed]
[50] Schönberg, K., Rudolph, J., Vonnahme, M., Yajnana-rayana, S.P., Cornez, I., Hejazi, M., Manser, A.R., Uhrberg, M., Verbeek, W., Koschmieder, S., et al. (2015) JAK Inhi-bition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Research, 75, 2187-2199. [Google Scholar] [CrossRef] 
[51] Mesa, R.A., Kiladjian, J.-J., Catalano, J.V., Devos, T., Egyed, M., Hellmann, A., McLornan, D., Shimoda, K., Winton, E.F., Deng, W., et al. (2017) SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis. Jour-nal of Clinical Oncology, 35, 3844-3850. [Google Scholar] [CrossRef] 
[52] Patel, A.A. and Odenike, O. (2020) The Next Generation of JAK Inhibitors: An Update on Fedratinib, Momelotonib, and Pacritinib. Current Hematologic Malignancy Reports, 15, 409-418. [Google Scholar] [CrossRef] [PubMed]
[53] Harrison, C., Vannucchi, A.M., Platzbecker, U., Cer-vantes, F., Gupta, V., Lavie, D., Passamonti, F., Winton, E.F., Dong, H., Kawashima, J., et al. (2018) Momelotinib ver-sus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib (SIMPLIFY 2): A Ran-domised, Open-Label, Phase 3 Trial. The Lancet Haematology, 5, e73-e81. [Google Scholar] [CrossRef] 
[54] Singer, J.W., Al-Fayoumi, S., Ma, H., Komrokji, R.S., Mesa, R. and Verstovsek, S. (2016) Comprehensive Kinase Profile of Pacritinib, a Nonmyelosuppressive Janus Kinase 2 Inhib-itor. Journal of Experimental Pharmacology, 8, 11-19. [Google Scholar] [CrossRef] 
[55] Mesa, R.A., Vannucchi, A.M., Mead, A.J., Egyed, M., Szoke, A., Su-vorov, A., Jakucs, J., Perkins, A., Prasad, R., Mayer, J., et al. (2017) Pacritinib versus Best Available Therapy for the Treatment of Myelofibrosis Irrespective of Baseline Cytopenias (PERSIST-1): An International, Randomised, Phase 3 Trial. The Lancet Haematology, 4, e225- e236. [Google Scholar] [CrossRef] 
[56] Harrison, C.N., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Knoops, L., Cervantes, F., Jones, M.M., Sun, K., McQuitty, M., et al. (2016) Long-Term Findings from COMFORT-II, a Phase 3 Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis. Leukemia, 30, 1701-1707. [Google Scholar] [CrossRef] [PubMed]
[57] Kiladjian, J.J., Zachee, P., Hino, M., Pane, F., Masszi, T., Harrison, C.N., Mesa, R., Miller, C.B., Passamonti, F., Durrant, S., et al. (2020) Long-Term Efficacy and Safety of Ruxolitinib versus Best Available Therapy in Polycythaemia Vera (RESPONSE): 5-Year Follow up of a Phase 3 Study. The Lancet Haematology, 7, e226-e237. [Google Scholar] [CrossRef] 
[58] Luo, Q., Xiao, Z. and Peng, L. (2021) Effects of Ruxolitinib on Infection in Patients with Myeloproliferative Neoplasm: A Meta-Analysis. Hematology, 26, 663-669. [Google Scholar] [CrossRef] [PubMed]
[59] Sadjadian, P., Wille, K., Griesshammer, M., Sadjadian, P., Wille, K. and Griesshammer, M. (2020) Ruxolitinib-Asso- ciated Infections in Polycythemia Vera: Review of the Litera-ture, Clinical Significance, and Recommendations. Cancers, 12, 3132. [Google Scholar] [CrossRef] [PubMed]
[60] Khalid, F., Damlaj, M., Al Zahrani, M., Abuelgasim, K.A. and Gma-ti, G.E. (2021) Reactivation of Tuberculosis Following Ruxolitinib Therapy for Primary Myelofibrosis: Case Series and Literature Review. Hematology/Oncology and Stem Cell Therapy, 14, 252-256. [Google Scholar] [CrossRef] [PubMed]
[61] Duan, M.-H., Cao, X.-X., Chang, L. and Zhou, D.-B. (2021) Risk of Hepatitis B Virus Reactivation Following Ruxolitinib Treatment in Patients with Myeloproliferative Neoplasms. Hematology, 26, 460-464. [Google Scholar] [CrossRef] [PubMed]
[62] Devos, T., Selleslag, D., Granacher, N., Havelange, V. and Benghiat, F.S. (2022) Updated Recommendations on the Use of Ruxolitinib for the Treatment of Myelofibrosis. Hema-tology, 27, 23-31. [Google Scholar] [CrossRef] [PubMed]
[63] Barraco, F., Greil, R., Herbrecht, R., Schmidt, B., Reiter, A., Willenbacher, W., Raymakers, R., Liersch, R., Wroclawska, M., Pack, R., et al. (2020) Real-World Non-Interventional Long-Term Post-Authorisation Safety Study of Ruxolitinib in Myelofibrosis. British Journal of Haematology, 191, 764-774. [Google Scholar] [CrossRef] [PubMed]
[64] Truong, B., Zhang, Y., Fahl, S., Cai, K.Q., Martinez, E., Al-Saleem, E.D., Gong, Y., Liebermann, D., Soboloff, J., Dunbrack, R., et al. (2021) ERK2 Substrate Binding Domains Perform Opposing Roles in Pathogenesis of a JAK2V617F- Driven Myeloproliferative Neoplasm. Blood, 138, 2547. [Google Scholar] [CrossRef] 

为你推荐